Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jack Russell who wrote (12840)	5/16/2014 9:15:20 AM
From: Rutgers	3 Recommendations Recommended By Howard Williams Jack Russell Mark Buczynski Respond to of 13111

Good stuff and the uplisting was nice, but the second abstract is the game changer, imho. Why? Perhaps better for mgt to save it for another day because the PR is silent on the topic, but I see that it has been mentioned to some extent on other boards. I am also not convinced that the market has digested the news and obviously I do not believe in efficient markets...here's the reason why I purchased more and more and more the last two months. You like to play connect the dots? Go back to see who has worked on the past studies. Now look again to see who is added to the second abstract - Jeffrey Weber. You have to look hard because his name is not mentioned in the most recent PR and it is not even listed at the top of the author list. So, what's the big deal, you ask? I guess if I was new to the game, I probably wouldn't think much of it, if I thought at all, but I am OTTG. Putting aside his reputation, among other things, when you have a chance, take a look at his disclosures (not for this abstract - you'll need to look at his older ones - hey, due your own DD like I did a long time ago!). As many of you probably know, funding sources are a lifeblood for researchers -- now, connect those dots!